A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.

Trial Profile

A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Simvastatin; TAP 311
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Aug 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top